CANCER ANTIBODIES VACCINES/ADJUVANTS & DELIVERY
17-19 September 2014, Switzerland (INOVIO will co-sponsor this conference)
"This CAVAD 2014 conference brings together
experts in both fields of mabs and vaccines to address these important issues.
CAVAD 2014 will offer a new international forum to review the current state of research and development of monoclonal antibodies and vaccines for cancer therapy".
SCIENTIFIC ADVISORY PANEL
Niranjan Sardesai (Inovio Inc., Blue Bell, Pennsylvania, USA)
(other co-chairs listed on conference site)
CAVAD 2014 will include keynote presentations from leading researchers, submitted oral and poster presentations, and special discussion/panel sessions
1-Abstracts for both oral and poster presentation are called for in the principal topics to be covered at CAVAD 2014 which include:
2-Autoimmunity and cancer
Both mabs and vaccines are trying to harness the immune system to recognise and
attack self/modified antigens on cancer cells. As autoimmunity does this very effectively,
inducing both T cell and antibody responses, there are good lessons to learn for cancer
As vaccines target intracellular antigens, presented as peptides on MHC molecules, and
Mabs target cell surface proteins there is obvious synergy in combining these approaches.
Indeed both cellular and humoral immunity are used in the successful attack on pathogens.
There are still very few approved adjuvants for vaccines that stimulate cellular immunity,
however new TLR agonists are being developed and the recent approval of a mab targeting
CTLA-4 and trials with anti-PD.1 mabs suggest novel approaches/combinations.
High avidity CD8 T cells, cytotoxic CD4s and direct killing/growth inhibiting mabs have all
been shown to mediate potent anti-tumour responses.